Nav: Home

Fred Hutch researcher receives grant for esophageal cancer screening study

March 10, 2016

Dr. William Grady, a clinical researcher and cancer geneticist at Fred Hutch, has been awarded a $180,000 grant from the DeGregorio Family Foundation for Gastric and Esophageal Cancer Research and the Price Family Foundation for a two-year project to develop a better way to identify people at highest risk for esophageal adenocarcinoma, the most common cancer of the esophagus.

Incidence of esophageal cancer is rapidly increasing in the United States. Last year, roughly 20,000 Americans died of it, which is more than a fivefold increase compared to the early 1970s.

The risk of adenocarcinoma increases with age, obesity and tobacco use. However, it is tenfold higher for individuals with Barrett's esophagus, a change in the esophageal lining that occurs in people who have chronic heartburn and gastroesophageal reflux. Cancer in patients with Barrett's esophagus can be prevented or treated successfully if caught early by endoscopy, a medical exam that allows doctors to look at the lining of the esophagus.

Endoscopies, unfortunately, are unpleasant and intrusive, and because just a fraction of those with Barrett's esophagus ever develop cancer, most people with the condition likely do not need them. The problem is that doctors have no way to tell which patients with Barrett's esophagus are at the highest risk for cancer. Grady's team aims to find a simple way to spot those patients who should get frequent endoscopies, while sparing others unnecessary discomfort.

He and research partner Dr. Georg Luebeck, a computational biologist and member of the Public Health Sciences Division at Fred Hutch, plan to achieve this with a test that can accurately determine the biological age of esophageal tissue, which results from biochemical wear and tear ? and differs from chronological age, as told by the calendar. Their focus is on detecting a process of chemical build-up on DNA, called DNA methylation, which Grady likens to rust. More "rust" means faster biological aging and presumably a higher risk of cancer.

With the funding from this new grant, Grady and Luebeck will compare the "rust" profiles in tissue samples of Barrett's esophagus patients who developed esophageal cancer with those who did not. Their goal is to use any differences between the profiles as the basis of a screening test that can tell Barrett's esophagus patients in the future whether they should start getting endoscopies and how often they should get them.

"The biological age of the esophagus will allow us to determine the true cancer risk for someone with Barrett's esophagus," said Grady, who is a member of Fred Hutch's Clinical Research Division and a practicing physician at Seattle Cancer Care Alliance. "We think a person with an older esophagus will have a higher cancer risk than a person with a young esophagus."
The DeGregorio Family Foundation raises funds to financially support critical research grants to facilitate early detection and effective treatment therapies for the deadly diseases of stomach and esophageal cancer.

Lynn DeGregorio, founder and president of the foundation, said of the award, "This year was our most competitive application process yet. The DeGregorio Family Foundation, along with a major contribution by the Price Family Foundation, are happy to support Dr. Grady's research. We believe the science proposed is novel and innovative and will feasibly lead to a better understanding of esophageal cancer."

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit or follow Fred Hutch on Facebook, Twitter or YouTube.

Fred Hutchinson Cancer Research Center

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at